Texas Children’s Faculty Earn National Leadership Roles Advancing Pediatric Hematology and Oncology
Recent leadership appointments and program selections highlight the expertise of our Hematology, Oncology, and Bone Marrow Transplant faculty and their impact on care for children with cancer and serious blood disorders.
Congratulations to the following individuals, pictured above from left to right, top to bottom:
Sarah Kappa, MD, was selected for the FDA-ASPHO Pediatric Hematology/Oncology Educational Program, an eight-month program that provides training in pediatric drug development, clinical trials and the regulatory review process. The 2026 cohort is limited to 20 early-career clinicians and researchers.
Alexander Ngwube, MD, was appointed Co-Chair of the Scientific Executive Committee for the Sickle Cell Transplant Advocacy and Research Alliance. In this role, he is helping guide research and expand awareness, access and effectiveness of potentially curative therapies for sickle cell disease, including blood and marrow transplantation and gene therapy.
Zach Prudowsky, MD, was selected for the FDA-ASPHO Pediatric Hematology/Oncology Educational Program, an eight-month program limited to 20 early-career clinicians and researchers. Through interactive sessions and case discussions, he is receiving training in pediatric drug development, clinical trials and the regulatory review process.
Omar Shakeel, MD, was appointed to the American Society of Pediatric Hematology/Oncology Section on Hematology Oncology Review Group for Supportive Care. Through this role, he is contributing to education, policy and equitable care initiatives across the field.
Congratulations to all four faculty members on these well-deserved opportunities to lead and contribute.